TriStar Health - May 26, 2017

Bone marrow transplant pharmacist receives regional recognition

Mohammed Elayan, PharmD, BCOP, is a bone marrow transplant and hematology/oncology clinical pharmacist at the Sarah Cannon Cancer Institute at TriStar Centennial Medical Center. He’s also a recipient of the 2016 HCA Innovators Award for TriStar Division. He was recognized for his research and work on chemotherapy dosage intensity.

Mohammed Elayan hematology oncology pharmacist nashville

Staggering chemotherapy dosage

Chemotherapy can be dosed kinetically to achieve a total desired exposure. In this instance, the total desired dosage is divided equally across each dosing day.

Mohammed’s concept involves staggering the dosages of chemotherapy across the dosing days to minimize the amount of waste.

He attributes his innovation to the work from his progressive and interdisciplinary team that has helped with time-staggering treatment.

Originally, if a dose called for 100 mg total over a four day period, staff would administer 25 mg daily for four days. However, vials contained 20 mg of chemotherapy, adding up to 15 mg of waste each day from using four extra vials.

Mohammed tested staggering the dose of chemotherapy to 30 mg for two days followed by 20 mg for the following two days. In turn, staff decreased the amount of waste to only two vials and there were no results of toxicity to the patients.

 

Improving care for cancer patients

Not only does it improve patient outcomes, but it also improves hospital efficiencies and saves money that can be used to provide care for more patients.

“I am humbled daily to provide care for our cancer patients,” said Mohammed. “Their strength and resolve in the face of a life-threatening disease provides the motivation to remain committed to their care each and every day.”

Mohammed attributes his innovation to the work from his progressive and interdisciplinary team

His dosage theory is being implemented currently at TriStar Centennial and Methodist Hospital in San Antonio, Texas, but he hopes to pilot it throughout the Sarah Cannon Blood Cancer Network.